JMJD2D is also identified as a prognostic marker for clear cell RCC (ccRCC), as the patients with low JMJD2D expression have a longer survival time after surgery, and pharmacological inhibition of JMJD2D can suppress the proliferation and angiogenesis of ccRCC both in vitro and in vivo by reducing the expression of JAG1 and VEGFR3 [107]. This evidence concerns the gene FLT4 and nonpapillary renal cell carcinoma.